P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Rayid Abdulqawi; Rachel Dockry; Kimberley Holt; Gary Layton; Bruce G. McCarthy; Anthony P. Ford; Jaclyn A. Smith

doi:10.1016/S0140-6736(14)61255-1

P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Rayid Abdulqawi, Rachel Dockry, Kimberley Holt, Gary Layton, Bruce G. McCarthy, Anthony P. Ford, Jaclyn A. Smith

Division of Immunology, Immunity to Infection and Respiratory Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1198-1205
Number of pages	7
Journal	The Lancet
Volume	385
Issue number	9974
DOIs	https://doi.org/10.1016/S0140-6736(14)61255-1
Publication status	Published - 28 Mar 2015

Access to Document

10.1016/S0140-6736(14)61255-1

Cough monitoring system facilitates clinical trials and enables development of treatments for patients with refractory chronic cough
Jacky Smith (Participant), Kevin Mcguinness (Participant) & Ashley Woodcock (Participant)
Impact: Health and wellbeing, Economic

Cite this

@article{f82997b863cf410a91e15089465f014c,

title = "P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.",

author = "Rayid Abdulqawi and Rachel Dockry and Kimberley Holt and Gary Layton and McCarthy, {Bruce G.} and Ford, {Anthony P.} and Smith, {Jaclyn A.}",

year = "2015",

month = mar,

day = "28",

doi = "10.1016/S0140-6736(14)61255-1",

language = "English",

volume = "385",

pages = "1198--1205",

journal = "The Lancet",

issn = "0140-6736",

publisher = "The Lancet",

number = "9974",

}

TY - JOUR

T1 - P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

AU - Abdulqawi, Rayid

AU - Dockry, Rachel

AU - Holt, Kimberley

AU - Layton, Gary

AU - McCarthy, Bruce G.

AU - Ford, Anthony P.

AU - Smith, Jaclyn A.

PY - 2015/3/28

Y1 - 2015/3/28

U2 - 10.1016/S0140-6736(14)61255-1

DO - 10.1016/S0140-6736(14)61255-1

M3 - Article

VL - 385

SP - 1198

EP - 1205

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9974

ER -

P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study.

Access to Document

Impacts

Cough monitoring system facilitates clinical trials and enables development of treatments for patients with refractory chronic cough

Cite this